India Rheumatoid Arthritis Drugs Market Outlook to 2028

India Rheumatoid Arthritis Drugs Market Overview

India's rheumatoid arthritis drugs market reached USD 850 Mn in 2023, driven by a surge in cases to 1.2 Mn people and demand for advanced treatments like biologics and DMARDs.

USD 550 Mn in 2018, the market surged due to biologic drugs, better diagnostics, and higher healthcare spending.

Cipla, Sun Pharma, Dr. Reddy’s, Lupin, Zydus Cadila, leveraging extensive product ranges and R&D investments for market dominance.

High treatment costs, rural access limitations, long-term drug side effects, and competition from traditional therapies like Ayurveda and homeopathy are few of the challenges.

Rising arthritis cases, aging population, treatment advancements, healthcare spending, and supportive government policies are driving the market.

India Rheumatoid Arthritis Drugs Market Analysis

The Indian Rheumatoid Arthritis drugs market was valued at USD 850 Mn in 2023 along with CAGR of 7.1% during the period of 2018-2023.

DMARDs, NSAIDs, corticosteroids, and JAK inhibitors are the major product categories, with emerging biologic therapies gaining traction.

Methotrexate, a DMARD, remains a cornerstone therapy for its efficacy, cost-effectiveness, and longstanding use in RA management.

Patients prioritize treatments offering effective symptom relief, disease control, affordability, and minimal side effects.

Abbott Laboratories' dominance is attributed to its extensive experience, trusted brand reputation, and diverse portfolio, including blockbuster biologic Humira (adalimumab).

DMARDs continue to dominate, providing both symptomatic relief and disease-modifying effects, aligning with long-term management goals.

Biologic therapies, led by Humira, are driving market growth, buoyed by increasing patient awareness, improved accessibility, and expanded insurance coverage.

India Rheumatoid Arthritis Drugs Market Segmentation

The Indian Rheumatoid Arthritis Drugs market can be segmented based on several factors:

By Drug Class: In 2023, disease-modifying antirheumatic drugs (DMARDs) lead the India rheumatoid arthritis drugs market, with methotrexate as the dominant sub-segment. Methotrexate's established efficacy and safety, lower cost, and status as the first-line treatment for most rheumatoid arthritis patients contribute to its prominence.

By Route of Administration: In 2023, the India rheumatoid arthritis drugs market shows a preference for oral administration, driven by ease of use, better patient compliance, and convenience in dosing. Injectable drugs are also significant, favored for their faster onset of action and higher effectiveness in severe cases or when oral medications are not sufficient.

By Distribution Channel: In 2023, the India rheumatoid arthritis drugs market is mainly served by hospital pharmacies, which lead due to their access to specialized treatments and expert advice. Retail pharmacies come next, thanks to their widespread availability and convenience. Online pharmacies are also growing, driven by the rise of e-commerce and often lower prices.

India Rheumatoid Arthritis Drugs Market Competitive Landscape

A diverse product portfolio, including conventional DMARDs, biologics, and JAK inhibitors, enhances market presence and meets varying patient needs. Cipla offers a wide range of both generic and branded medications.

Extensive distribution networks ensure wide availability of medications across urban and rural areas, enhancing market penetration. Dr. Reddy’s Laboratories has a distribution network covering over 100,000 pharmacies.

Investment in research and development drives innovation, leading to the introduction of advanced therapies and improved treatment options. Lupin Limited spends a significant portion of its revenue on R&D for new drug development.

A strong brand reputation builds trust and loyalty among healthcare professionals and patients, supporting long-term market leadership. Abb Vie India is known for its innovative biologic therapies.

India Rheumatoid Arthritis Drugs Industry Analysis

India Rheumatoid Arthritis Drugs Market Growth Drivers

Increasing Prevalence: Rheumatoid arthritis affects over 1.2 million Indians, spurring demand for effective treatments and medications, driving market growth.

Aging Population: With the geriatric population projected to reach 11.1% of total population by 2025, the demand for drugs targeting age-related conditions like rheumatoid arthritis is rising, amplifying market opportunities.

Healthcare Expenditure: Projected to hit USD 200 billion by 2028, increased healthcare spending supports advanced therapies adoption and enhances treatment accessibility, bolstered by government initiatives to fortify healthcare infrastructure.

Drug Development: Innovations like biologics and JAK inhibitors offer more effective rheumatoid arthritis treatments, advancing disease management and patient outcomes.

Awareness and Diagnosis: Improved awareness and diagnostic facilities enable early rheumatoid arthritis detection and treatment, aided by healthcare provider initiatives and patient advocacy efforts.

India Rheumatoid Arthritis Drugs Market Challenges:

High Treatment Costs: Biologic therapies for rheumatoid arthritis can cost thousands annually, creating financial strain. For instance, in India, the yearly expense for biologics ranges from USD 3,000 to USD 10,000, limiting accessibility.

Limited Rural Access: Rural areas lack specialist care and advanced treatments, affecting disease management. About 70% of India's population resides in rural regions, where healthcare infrastructure is deficient, exacerbating treatment disparities.

Lack of Awareness: Poor understanding of RA symptoms, early detection, and treatment options delays management, leading to poorer outcomes. Public awareness campaigns are essential to educate about RA and the importance of prompt medical care.

Counterfeit Drugs: Counterfeit RA medications pose safety risks, being ineffective or harmful. Stringent regulation, quality control, and public education are vital to combat counterfeiting.

India Rheumatoid Arthritis Drugs Market Recent Developments:

Cipla acquired a stake in a biotech firm specializing in biologic drugs to bolster its product range and market presence in rheumatoid arthritis treatment.

Sun Pharma introduced a biosimilar of adalimumab, providing a more affordable option for advanced rheumatoid arthritis therapy.

Reddy’s Laboratories launched an improved methotrexate formulation, enhancing disease management and patient adherence.

Lupin teamed up with a digital health platform to offer teleconsultation services, enhancing access to specialist care for rheumatoid arthritis patients.

Zydus Cadila initiated a sustainability drive to cut carbon emissions and promote eco-friendly manufacturing practices, aligning with global environmental objectives.

India Rheumatoid Arthritis Drugs Market Government Initiatives:

Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP): PMBJP provides quality generic medicines across India, benefiting patients with chronic ailments like rheumatoid arthritis through its extensive distribution network.

Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY): AB-PMJAY covers over 50 crore beneficiaries, offering financial protection for secondary and tertiary hospitalization costs, including treatments for rheumatoid arthritis.

National List of Essential Medicines (NLEM): NLEM includes crucial drugs like those for rheumatoid arthritis, ensuring their availability and affordability across healthcare facilities in India.

Research and Development Initiatives: Government-funded R&D initiatives support innovation in healthcare, potentially leading to new treatments and improved outcomes for patients with rheumatoid arthritis.

National Health Mission (NHM): NHM has expanded healthcare facilities, including over 5,000 primary health centers, improving access for chronic conditions like rheumatoid arthritis nationwide.

India Rheumatoid Arthritis Drugs Future Market Outlook

The Indian RA drugs market is projected to have significant growth driven by several key factors. The rising prevalence of RA due to an aging population will continue to fuel demand for effective medications.

Technological Integration: Increasing integration of advanced technologies, such as AI and machine learning, in drug development and patient care will enhance treatment efficacy and disease management.

Sustainability Focus: Continued emphasis on sustainability and environmentally friendly practices by pharmaceutical companies will attract eco-conscious consumers and align with global regulatory trends.

Customized Solutions: Demand for personalized medicine and tailored treatment plans will increase, providing new opportunities for pharmaceutical companies to innovate and expand market reach.

Government Support: Continued government support through initiatives and policies, including subsidies, research funding, and healthcare infrastructure development, will bolster market growth and ensure a stable and attractive environment for both producers and consumers.
Please Note: It will take 5-7 business days to complete the report upon order confirmation